Nazila Assasi

567 total citations
32 papers, 412 citations indexed

About

Nazila Assasi is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health and Physiology. According to data from OpenAlex, Nazila Assasi has authored 32 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 6 papers in Public Health, Environmental and Occupational Health and 6 papers in Physiology. Recurrent topics in Nazila Assasi's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Inflammatory Bowel Disease (5 papers) and Healthcare cost, quality, practices (4 papers). Nazila Assasi is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Inflammatory Bowel Disease (5 papers) and Healthcare cost, quality, practices (4 papers). Nazila Assasi collaborates with scholars based in Canada, Iran and United States. Nazila Assasi's co-authors include Ron Goeree, Jean‐Éric Tarride, Kaitryn Campbell, Gord Blackhouse, Daria O’Reilly, Kathryn Gaebel, Lisa Schwartz, Feng Xie, Mitchell Levine and James M. Bowen and has published in prestigious journals such as Clinical Therapeutics, Value in Health and Journal of Crohn s and Colitis.

In The Last Decade

Nazila Assasi

28 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nazila Assasi Canada	14	137	76	72	69	56	32	412
Christoph Ohlmeier Germany	11	52 0.4×	15 0.2×	59 0.8×	61 0.9×	53 0.9×	29	408
Nicole Yurgin United States	15	158 1.2×	22 0.3×	79 1.1×	43 0.6×	26 0.5×	33	720
Mark Rutkowski United States	14	33 0.2×	47 0.6×	37 0.5×	43 0.6×	30 0.5×	18	561
Peter Davey United Kingdom	4	104 0.8×	25 0.3×	35 0.5×	44 0.6×	71 1.3×	5	353
Zhuo Yang United States	15	42 0.3×	65 0.9×	157 2.2×	25 0.4×	128 2.3×	22	692
Cathy Anne Pinto United States	11	159 1.2×	18 0.2×	61 0.8×	88 1.3×	35 0.6×	29	509
Mohammad Keykhaei Iran	14	30 0.2×	15 0.2×	105 1.5×	35 0.5×	89 1.6×	45	516
Josh DeClercq United States	11	77 0.6×	12 0.2×	53 0.7×	18 0.3×	19 0.3×	42	346
Janet Roscoe Canada	14	43 0.3×	112 1.5×	25 0.3×	27 0.4×	98 1.8×	22	673
Michelle B Leavy United States	9	67 0.5×	18 0.2×	29 0.4×	44 0.6×	55 1.0×	37	305

Countries citing papers authored by Nazila Assasi

Since Specialization

Citations

This map shows the geographic impact of Nazila Assasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nazila Assasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nazila Assasi more than expected).

Fields of papers citing papers by Nazila Assasi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nazila Assasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nazila Assasi. The network helps show where Nazila Assasi may publish in the future.

Co-authorship network of co-authors of Nazila Assasi

This figure shows the co-authorship network connecting the top 25 collaborators of Nazila Assasi. A scholar is included among the top collaborators of Nazila Assasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nazila Assasi. Nazila Assasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Assasi, Nazila & Aleksandra Grobelna. (2017). Posaconazole for the Prophylaxis and Treatment of Invasive Aspergillosis: A Review of Clinical Effectiveness and Guidelines. 3 indexed citations

Assasi, Nazila, Jean‐Éric Tarride, Daria O’Reilly, & Lisa Schwartz. (2016). Steps toward improving ethical evaluation in health technology assessment: a proposed framework. BMC Medical Ethics. 17(1). 34–34. 25 indexed citations

Assasi, Nazila, Lisa Schwartz, Jean‐Éric Tarride, Daria O’Reilly, & Ron Goeree. (2015). BARRIERS AND FACILITATORS INFLUENCING ETHICAL EVALUATION IN HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care. 31(3). 113–123. 16 indexed citations

O’Reilly, Daria, James M. Bowen, Rolf J. Sebaldt, et al.. (2014). Evaluation of a chronic disease management system for the treatment and management of diabetes in primary health care practices in Ontario: an observational study.. PubMed. 14(3). 1–37. 9 indexed citations

Assasi, Nazila, Lisa Schwartz, Jean‐Éric Tarride, Kaitryn Campbell, & Ron Goeree. (2014). A systematic review of methodological frameworks for evaluation of ethical considerations in health technology assessment. Value in Health. 17(3). A200–A200.

Assasi, Nazila, Lisa Schwartz, Jean‐Éric Tarride, Kaitryn Campbell, & Ron Goeree. (2014). Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research. 14(2). 203–220. 48 indexed citations

O’Reilly, Daria, Kaitryn Campbell, Natasha Burke, et al.. (2013). HYPERBARIC OXYGEN THERAPY FOR DIABETIC ULCERS: SYSTEMATIC REVIEW AND META-ANALYSIS. International Journal of Technology Assessment in Health Care. 29(3). 269–281. 27 indexed citations

Assasi, Nazila, Lisa Schwartz, Jean‐Éric Tarride, Ron Goeree, & Feng Xie. (2012). Economic Evaluations Conducted for Assessment of Genetic Testing Technologies: A Systematic Review. Genetic Testing and Molecular Biomarkers. 16(11). 1322–1335. 12 indexed citations

Assasi, Nazila, Feng Xie, Gord Blackhouse, et al.. (2012). Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. Journal of Interventional Cardiac Electrophysiology. 35(3). 259–275. 11 indexed citations

10.

Blackhouse, Gord, Feng Xie, Mitchell Levine, et al.. (2012). Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.. PubMed. 19(2). e166–78. 8 indexed citations

11.

Assasi, Nazila, Lisa Schwartz, Jean‐Éric Tarride, Ron Goeree, & Feng Xie. (2011). PMD86 A Systematic Review of Economic Evaluations Conducted for Assessment of Genetic Testing Technologies. Value in Health. 14(7). A260–A260.

12.

Gaebel, Kathryn, Andrew McIvor, Feng Xie, et al.. (2011). Triple Therapy for the Management of COPD: A Review. COPD Journal of Chronic Obstructive Pulmonary Disease. 8(3). 206–243. 17 indexed citations

13.

Blackhouse, Gord, Nazila Assasi, Feng Xie, et al.. (2011). Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. Journal of Crohn s and Colitis. 6(1). 77–85. 27 indexed citations

14.

Blackhouse, Gord, Kathryn Gaebel, Feng Xie, et al.. (2010). Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Effectiveness and Resource Allocation. 8(1). 14–14. 42 indexed citations

15.

Assasi, Nazila, Gord Blackhouse, Feng Xie, et al.. (2010). Patient outcomes after anti TNF-α drugs for Crohn’s disease. Expert Review of Pharmacoeconomics & Outcomes Research. 10(2). 163–175. 9 indexed citations

16.

Assasi, Nazila, Gord Blackhouse, Feng Xie, et al.. (2009). Anti-TNF-alpha drugs for refractory inflammatory bowel disease: clinical- and cost-effectiveness analyses. 6 indexed citations

17.

Blackhouse, Gord, et al.. (2009). Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation. 7(1). 20–20. 35 indexed citations

18.

Xie, Feng, Gord Blackhouse, Nazila Assasi, et al.. (2009). Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura. Clinical Therapeutics. 31(5). 1082–1091. 15 indexed citations

19.

Tavafian, Sedigheh Sadat, et al.. (2005). A FOCAL GROUP STUDY OF PATIENT’S EXPERIENCES, PERCEPTIONS AND OPINIONS ABOUT NON-HEALTHY BEHAVIORS RESULTING IN LOW BACK PAIN. ACTA MEDICA IRANICA. 43(4). 282–286. 1 indexed citations

20.

Gholami, Kheirollah, Saeed Alipour Parsa, Gloria Shalviri, Mohammad Sharifzadeh, & Nazila Assasi. (2005). Anti-infectives-induced adverse drug reactions in hospitalized patients. Pharmacoepidemiology and Drug Safety. 14(7). 501–506. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact